...
首页> 外文期刊>The Journal of investigative dermatology. >Ameliorating skin-homing receptors on malignant T cells with a fluorosugar analog of N-acetylglucosamine: P-selectin ligand is a more sensitive target than E-selectin ligand.
【24h】

Ameliorating skin-homing receptors on malignant T cells with a fluorosugar analog of N-acetylglucosamine: P-selectin ligand is a more sensitive target than E-selectin ligand.

机译:使用N-乙酰氨基葡萄糖的氟糖类似物改善恶性T细胞上的皮肤归巢受体:P-选择素配体比E-选择素配体更敏感。

获取原文
获取原文并翻译 | 示例

摘要

Expression of E- and P-selectin ligands is required for T cell entry into skin. Sialyl Lewis X moieties are critical for ligand activity and are elevated on malignant skin-homing T cells. We hypothesize that these glycosylations are selectable targets for treating the dermal tropism associated with cutaneous lymphomas. In this study, we analyzed the efficacy of a novel 4-fluorinated analog of N-acetylglucosamine (GlcNAc) on E- and P-selectin ligands expressed by malignant skin-homing T cells. We also examined the specificity of 4-F-GlcNAc (2-acetamido-1,3,6-tri-O-acetyl-4-deoxy-4-fluoro-D-glucopyranose) action by contrasting the effects on sialyl Lewis X expression displayed by P-selectin glycoprotein ligand-1 (PSGL-1) with sialylated O-glycans expressed by CD43. Using parallel-plate flow analysis, we found that 4-F-GlcNAc elicited 5-fold more potent inhibition on P-selectin ligand activity than on E-selectin ligand activity. To determine whether glycosylations conferring E- and P-selectin ligand activities were inhibited, we analyzed the expression of sialyl Lewis X and sialyl-fucosylated core 2 O-glycan (CHO-131 antigen), respectively. We found that 4-F-GlcNAc treatment resulted in dose-dependent ablation of sialyl Lewis X and CHO-131 antigen expression on PSGL-1, whereas sialylated O-glycans on CD43 were minimally affected. These results indicate that 4-F-GlcNAc treatment can selectively downregulate the P-selectin ligand activity and potentially prevent dermal dissemination of cutaneous lymphomas.
机译:T细胞进入皮肤需要E和P选择素配体的表达。唾液酸化的路易斯X部分对于配体活性至关重要,并且在恶性皮肤归巢的T细胞上升高。我们假设这些糖基化是治疗与皮肤淋巴瘤相关的皮肤嗜性的选择性靶标。在这项研究中,我们分析了N-乙酰氨基葡萄糖(GlcNAc)的新型4氟化类似物对恶性皮肤归巢T细胞表达的E和P选择素配体的功效。我们还通过对比对唾液酸化的路易斯X表达的影响,研究了4-F-GlcNAc(2-乙酰氨基-1,3,6-三-O-乙酰基-4-脱氧-4-氟-D-吡喃葡萄糖)作用的特异性P-选择蛋白糖蛋白配体-1(PSGL-1)与CD43所表达的唾液酸化O-聚糖结合后的表达。使用平行板流动分析,我们发现4-F-GlcNAc引起的对P-选择蛋白配体活性的抑制作用是对E-选择蛋白配体活性的5倍。要确定是否抑制了赋予E-和P-选择素配体活性的糖基化,我们分别分析了唾液酸化Lewis X和唾液酸岩藻糖基化核心2 O-聚糖(CHO-131抗原)的表达。我们发现4-F-GlcNAc处理导致PSGL-1上唾液酸路易斯X和CHO-131抗原表达的剂量依赖性消融,而CD43上的唾液酸化O-聚糖受到的影响最小。这些结果表明4-F-GlcNAc治疗可以选择性地下调P-选择蛋白配体的活性并潜在地防止皮肤淋巴瘤的皮肤扩散。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号